IPP Bureau
Briefs: SMS Pharmaceuticals and Vimta Labs
By IPP Bureau - March 03, 2024
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Biomind Labs announces positive results of Phase 2 clinical trial of BMND08 for depression & anxiety in Alzheimer’s disease
By IPP Bureau - March 03, 2024
Clinical findings support the safety and efficacy of BMND08 at a maximum dosage of 12mg
USFDA inspects Shilpa Medicare’s bio-analytical laboratory in Hyderabad
By IPP Bureau - March 02, 2024
This newly set up Centre for bio-analytical testing has already received European Regulatory Authority clearance recently
Aurobindo Pharma receives USFDA approval for Fingolimod Capsules, 0.5 mg
By IPP Bureau - March 02, 2024
The product will be launched in March 2024
Warren Remedies commences commercial production of oral care products
By IPP Bureau - March 02, 2024
The production started from its greenfield manufacturing facility at Aurangabad in Maharashtra
Cabinet approves post of director for National Institute for One Health
By IPP Bureau - March 02, 2024
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Cipla incorporates JV company in USA
By IPP Bureau - March 02, 2024
Cipla completes transfer of Generics Business Undertaking
.jpg "Suven announces merger of Cohance Lifesciences")
Suven announces merger of Cohance Lifesciences
By IPP Bureau - March 01, 2024
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Biocon Biologics secures US market entry date for Bmab 1200
By IPP Bureau - March 01, 2024
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
Briefs: Eugia Pharma Specialities and Eugia SEZ
By IPP Bureau - March 01, 2024
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Pfizer Oncology hosts innovation day
By IPP Bureau - March 01, 2024
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
By IPP Bureau - February 29, 2024
BHL will undertake the development and supply of these molecules
TechInvention Lifecare breaks ground of its GCMC
By IPP Bureau - February 29, 2024
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
_in_Mizushima,_Japan.jpg "Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less")
Asahi Kasei offers pharmaceutical excipient Ceolus with nitrite concentration of 0.1 ppm or less
By IPP Bureau - February 29, 2024
Contributing to lower risk of potentially carcinogenic nitrosamine impurities in pharmaceuticals
Chemex Global inaugurates state-of-the-art API plant in Guwahati
By IPP Bureau - February 29, 2024
The plant will drive pharmaceutical innovation in the Northeastern India
